Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Collaboration by Quarter
CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M) ($M)
Vertex Pharmaceuticals CRISPR Collaboration: $10.9M in Q4 2023, down 198.2% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 10.9 | -198.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 7 | -48.1% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 8.30 | -31.4% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 5.80 | -40.8% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | -11.1 | – | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 13.5 | – | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 12.1 | – | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 9.80 | – | Form 10-Q (filed 2023-05-02) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Collaboration ($M), quarterly Q1 2022–Q4 2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-sga
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.